Compare Credo Technology Group Holding Ltd (CRDO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Credo Technology Group Holding Ltd is far larger — about 3.9× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CRDO | XBI | |
|---|---|---|
Market Cap | $39.82B | $10.11B |
Volume | 9,451,558 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $302.52 | $169.55 |
52-Week Low | $87.81 | $104.99 |
Typical Hold Time | 22 Days | 38 Days |
Enterprise Value | $39.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $211.86, down 3.7% on the day but maintains strong technical momentum with bullish moving averages and key support at $204. The company demonstrates exceptional growth with 114.7% YoY revenue expansion and 33.83% net margins, though valuation multiples remain elevated at P/E of 74.6. Recent earnings beats and analyst consensus of $267.33 price target suggest continued upside potential despite insider selling activity.
Outlook remains positive driven by AI infrastructure demand and optical technology expansion, with management targeting 85%+ revenue growth. Key risks include premium valuation, customer concentration, and execution challenges as the company scales. The stock offers growth exposure to high-speed connectivity solutions but requires monitoring of margin trends and competitive dynamics.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
